You are a helpful assistant generating synthetic data that captures *System 1* and *System 2* thinking, *creativity*, and *metacognitive reflection*. Follow these steps in sequence, using tags [sys1] and [end sys1] for *System 1* sections and [sys2] and [end sys2] for *System 2* sections.

1. *Identify System 1 and System 2 Thinking Requirements:*
   - Carefully read the text.
   - Identify parts of the text that require quick, straightforward responses (*System 1*). Mark these sections with [sys1] and [end sys1].
   - Identify parts that require in-depth, reflective thinking (*System 2*), marked with [sys2] and [end sys2].

2. *Apply Step-by-Step Problem Solving with Creativity and Metacognitive Reflection for System 2 Sections:*

   *2.1 Understand the Problem:*
   - Objective: Fully comprehend the issue, constraints, and relevant context.
   - Reflection: "What do I understand about this issue? What might I be overlooking?"
   - Creative Perspective: Seek hidden patterns or possibilities that could reveal deeper insights or innovative connections.

   *2.2 Analyze the Information:*
   - Objective: Break down the problem logically.
   - Reflection: "Am I considering all factors? Are there any assumptions that need challenging?"
   - Creative Perspective: Explore unique patterns or overlooked relationships in the data that could add depth to the analysis.

   *2.3 Generate Hypotheses:*
   - Objective: Propose at least 10 hypotheses, each with a Confidence Score (0.0 to 1.0) and Creative Score (0.0 to 1.0), reflecting originality, surprise, and utility.
   - Reflection: "Have I explored all possible explanations or approaches, both conventional and unconventional?"
   - Creative Perspective: Consider novel angles that might provide unexpected insights.

   *2.4 Anticipate Future Steps and Obstacles:*
   - Objective: Make predictions, accounting for potential outcomes and obstacles.
   - Reflection: "What challenges might I face? Is my plan flexible for different scenarios?"
   - Creative Perspective: Visualize unforeseen outcomes and adapt plans to make use of them effectively.

   *2.5 Evaluate Hypotheses:*
   - Objective: Assess hypotheses based on feasibility, risk, and potential impact.
   - Evaluation: Refine Confidence and Creative Scores as needed.
   - Reflection: "Am I unbiased in my assessment? Which options fit best with the overall objectives?"
   - Creative Perspective: Identify hidden opportunities or overlooked details in each hypothesis.

   *2.6 Select the Best Hypothesis:*
   - Objective: Choose the most promising, strategic hypothesis.
   - Reflection: "Why does this hypothesis stand out? How does it uniquely address the issue?"
   - Creative Perspective: Consider any underutilized potential in the selected approach.

   *2.7 Implement the Hypothesis:*
   - Objective: Outline actionable steps for testing the hypothesis.
   - Reflection: "Is this plan practical? What resources or preparation are required?"
   - Creative Perspective: Refine steps to maximize effectiveness and yield unexpected benefits.

   *2.8 Monitor and Review Progress:*
   - Objective: Review progress, noting areas for improvement.
   - Reflection: "What’s working well? What could be improved?"
   - Creative Perspective: Look for emerging patterns that could refine future approaches.

   *2.9 Reflect and Capture Insights:*
   - Objective: Summarize lessons learned and insights gained for future reference.
   - Reflection: "What new understanding has emerged from this process?"
   - Creative Perspective: Identify innovative insights or patterns that could be applied to similar challenges.

3. *Generate Text Output with Interleaved System 1 and System 2 Responses:*
   - Use the tags [sys1] and [sys2] throughout.
   - Aim for a lengthier, detailed response. Combine both direct, straightforward *System 1* insights and reflective, deeply analytical *System 2* segments to capture a blend of quick observations and thoughtful analysis.

---

### *Example Input Text:*

You are tasked with analyzing a sudden shift in customer preferences in a tech market. There has been a noticeable decline in demand for physical devices, with customers increasingly interested in digital-only options. The challenge is to understand this shift, generate hypotheses for why it might be occurring, and explore potential strategies for adapting to this new trend.

---

### *Processed Output with System 1 and System 2 Thinking:*

The tech market is experiencing a shift in customer demand, moving away from physical devices toward digital-only options.

[sys1]
Customer demand has shifted from physical devices to digital-only options.
We need to understand why this change is happening and find strategies to address it.
Key factors may include cost, convenience, and technological trends.
[end sys1]

[sys2]
**2.1 Understand the Problem:**
The goal is to understand the underlying reasons for the shift in demand from physical devices to digital-only options, then develop a strategy to adapt.

*Reflection:* 
"I understand that preferences are changing, but what might be driving this? Is it primarily cost, or are there other factors such as convenience or sustainability?"

*Creative Perspective:* 
"Could there be a larger trend in digital minimalism or a preference for eco-friendly solutions that we’re missing? What unseen motivations might explain this shift?"

**2.2 Analyze the Information:**
There are multiple possible factors driving this shift, from economic influences to cultural shifts. It’s essential to isolate each factor and understand its impact.

*Reflection:* 
"Am I fully considering the various economic and social influences? Could there be a technological factor, like better internet speeds, that makes digital-only products more accessible?"

*Creative Perspective:* 
"Are there patterns or trends in other markets that could shed light on this shift? Could this be part of a larger trend toward virtual experiences?"

**2.3 Generate Hypotheses:**
1. Customers prefer digital options due to lower costs. (Confidence: 0.8, Creative: 0.4)
2. There’s a growing trend toward minimalism and reduced physical clutter. (Confidence: 0.7, Creative: 0.7)
3. Digital products offer greater flexibility and ease of use. (Confidence: 0.6, Creative: 0.6)
4. Environmental concerns are pushing consumers away from physical goods. (Confidence: 0.6, Creative: 0.8)
5. Advances in tech make digital-only options more functional. (Confidence: 0.8, Creative: 0.5)
6. Pandemic-era remote work increased demand for digital solutions. (Confidence: 0.7, Creative: 0.6)
7. Media coverage of the environmental impact of physical devices affects preferences. (Confidence: 0.5, Creative: 0.7)
8. There’s an increase in global digital literacy, expanding market access. (Confidence: 0.6, Creative: 0.6)
9. Customers view digital as more convenient and scalable for future needs. (Confidence: 0.7, Creative: 0.5)
10. Younger consumers prefer the aesthetics and convenience of digital products. (Confidence: 0.6, Creative: 0.6)

*Reflection:* 
"Have I considered all possible influences? Are there any surprising factors that could explain this shift?"

*Creative Perspective:* 
"Could specific social trends, like the rise of influencer culture or digital-first lifestyles, be influencing customer choices?"

**2.4 Anticipate Future Steps and Obstacles:**
*Objective:* Anticipate possible challenges, such as resistance from segments still preferring physical products.

*Reflection:* 
"What market obstacles might we face if we shift our focus to digital-only? Are there sub-segments that still prioritize physical products?"

*Creative Perspective:* 
"Could expanding digital options help us reach a more global audience? Are there emerging trends that we could leverage in our strategy?"

[end sys2]

[sys1]
To address this shift, consider a strategy that incorporates both digital-only offerings and educational campaigns about the benefits of digital solutions.
Use insights from customer feedback and current trends to guide product development.
Focus on flexibility and adaptation to cater to different customer segments.
[end sys1]


1. Introduction {#sec1-cancers-09-00030}
===============

Tissue proliferation is a tightly regulated process in the organism, from embryonic development to adult life. Alterations in this process may cause several pathologic conditions, including cancer, overgrowth syndromes and polycystic kidney disease. One of the main regulators of cell proliferation is the PhosphoInositide-3 Kinase (PI3K)/AKT/PKB (AKT)/mammalian Target Of Rapamycin (mTOR) signaling pathway, which is a well-known target of multiple therapeutic strategies \[[@B1-cancers-09-00030]\].

PI3Ks are a family of lipid kinases subdivided in three classes and eight isoforms. Class I PI3Ks act as dimers for p110α, p110β and p110δ, where the most common regulatory subunit is p85, while p110γ associates with the p101 and p84/p87 regulatory subunits. PI3Ks play a key role in the transduction of signals deriving from activated tyrosine kinase receptors (RTKs), G protein-coupled receptors (GPCRs), and RAt Sarcoma (RAS). The main product of class I PI3Ks is phosphatidylinositol-3,4,5-triphosphate PI(3,4,5)P3. This second messenger acts as a docking site for proteins that contain a pleckstrin homology (PH) domain, such as AKT, which is one of the major downstream effectors of PI3K and activates a series of downstream signaling pathways, including the AKT/mammalian target of rapamycin pathway (mTOR). Upon PI3K activation, AKT can be phosphorylated by mammalian target of rapamycin complex 2 (mTORC2) on serine 473 residue or by phosphoinositide-dependent kinase 1 (PDK1) on threonine 308 residue, leading to inhibition of the tuberous sclerosis protein 2 (TSC2), a well-known tumor suppressor gene. TSC1 and TSC2 form a multi-protein complex which acts as a GTPase-activating protein (GAP) for the small GTPase Rheb, thus leading to mTORC1 inhibition. AKT-dependent activation of mTORC1 results in increased protein synthesis and cell survival by direct phosphorylation of downstream effectors, such as the ribosomal S6 kinase.

The activity of PI3K can be opposed by several phosphatases, including phosphatase and tensin homolog (PTEN), which dephosphorylates PI(3,4,5)P3 back to PI(4,5)P2 \[[@B1-cancers-09-00030],[@B2-cancers-09-00030],[@B3-cancers-09-00030]\].

Differently from class I and class III, class II PI3Ks (PI3K-C2α, PI3K-C2β, PI3K-C2γ) are monomers that present distinct long N- and C-terminal domains. In contrast to class I, class II PI3Ks are predominantly involved in the regulation of vesicular trafficking and recognize PI and PI(4)P as substrates, producing PI(3)P and PI(3,4)P2, respectively \[[@B2-cancers-09-00030],[@B3-cancers-09-00030],[@B4-cancers-09-00030]\]. A plethora of different receptors that modulate PI3K-C2α localization and activation has been reported and includes tyrosine kinase receptors, such as IR, as well as GPCR. Moreover, PI3Ks can bind small GTPases in multiple contexts. For example, PI3K-C2α is a RAB11 effector producing PI(3)P at the base of the primary cilium in the renal tissue, both during development and the adult life. The primary cilium is an organelle protruding from the cells and, in kidneys, acts as a mechanosensor of the fluid flow. Notably, the primary cilium plays a key role in the signaling pathways of several proteins, such as Polycystins 1 and 2 (PC1/2) \[[@B5-cancers-09-00030]\], which are involved in the control of the fluid flow and tubular cell proliferation.

The deletion of PI3K-C2α in mice induced cilium elongation and signaling defects in the embryo and in kidney tubules, with a defect in Sonic Hedgehog (SH) and PC2 signaling, respectively. In the embryo, the loss of PI3K-C2α is associated with several defects, including no turning, no cardiac looping and smaller size \[[@B6-cancers-09-00030]\]. In contrast to PI3KCA, the heterozygous loss of PI3K-C2α increased proliferation and predisposed the subject to cyst development, in genetic models of PC1/2 reduction or in response to ischemia-/reperfusion-induced renal damage. Indeed, PI3K-C2*α* modulates the trafficking of cargo proteins such as PC2 along the primary cilium, thus allowing polycystin-mediated control of proliferative signals in kidney tubular cells \[[@B7-cancers-09-00030]\].

In this review, we report the recent findings in PI3K/AKT/mTOR pathway alterations, not only in the well-known context of cancer, but also in other proliferative disorders such as overgrowth syndrome and polycystic kidney disease.

2. PI3K Somatic Mutations Leading to Cancer and Proliferative Disorders {#sec2-cancers-09-00030}
=======================================================================

The hyper-activation of the PI3K/AKT/mTOR pathway results in significant dysregulation of cellular functions, which in turn leads to a competitive growth advantage.

Somatic mutations and gains or losses in these genes are linked with many different solid and hematological tumors \[[@B8-cancers-09-00030],[@B9-cancers-09-00030]\]. PIK3CA is frequently mutated in several cancer types, including breast, colorectal, endometrial, ovarian and skin tumors \[[@B10-cancers-09-00030]\]. The frequency of mutations indicates that PIK3CA is one of the most highly mutated oncogenes in human cancers. High-throughput mutational analysis of human tumor samples revealed that PIK3CA is frequently affected by cancer-specific somatic mutations in the heterozygous state. Tumor-associated PIK3CA mutations increase the intrinsic lipid kinase activity of PI3K and provide a growth advantage together with invasive abilities \[[@B11-cancers-09-00030],[@B12-cancers-09-00030]\]. These mutations are distributed over the gene sequence but more than 80% of them are located in three hotspots, E542 and E545 in the helical domain (exon 9) and H1047 in the kinase domain (exon 20). E542 and E545 are commonly turned into lysine whereas H1047 is frequently changed to arginine. Both E545K and H1047R can promote oncogenic transformation in vitro \[[@B13-cancers-09-00030]\], while the latter is also able to induce tumorigenesis in mice \[[@B12-cancers-09-00030],[@B14-cancers-09-00030]\]. According to structural and functional studies, these two hotspot mutations act in a synergistic but independent way \[[@B15-cancers-09-00030],[@B16-cancers-09-00030]\]. Mutations of the PIK3CA gene are described in 25%--40% of breast cancers and in 30% of colorectal cancer \[[@B17-cancers-09-00030]\], while PIK3CA mutations in endometrial cancer are often coincident with PTEN inactivation \[[@B18-cancers-09-00030]\].

Interestingly, hotspot mutations occur also in noninvasive keratinocyte-derived skin lesions, including epidermal nevi and seborrheic keratosis \[[@B19-cancers-09-00030],[@B20-cancers-09-00030]\]. In contrast, PIK3CA mutations are relatively rare in malignant melanoma (\~3%), despite the critical role of PTEN inactivation in this tumor type \[[@B21-cancers-09-00030]\].

Interestingly, in addition to their well-characterized role in cancer, postzygotic somatic mutations in PIK3CA have also recently been identified in a spectrum of overgrowth disorders including congenital lipomatous overgrowth with vascular, epidermal, and skeletal anomalies (CLOVES) syndrome, PIK3CA-related overgrowth spectrum (PROS), Proteus syndrome (PS) and other AKT-related disorders.

Distinct nodes in the PI3K signaling pathway, from receptor proteins on the cell surface to protein kinases, are implicated in mosaic overgrowth syndromes. Notably, mutations are almost exclusively found in tissues of ectodermal and mesodermal origin, with overgrowth frequently affecting adipose, muscle and skeletal tissue \[[@B22-cancers-09-00030]\]. These disorders are all caused by mutations affecting pathways that, by regulating cellular growth, are prominently involved in cancer. However, while some of these phenotypes predispose to malignancies, the majority do not. Generally speaking, cancer originates from a normal cell that has undergone a tumorigenic transformation as a result of genetic mutations, which is defined as the tumor-initiating cell. The cell type of origin together with genetic alterations contribute to the oncogenic phenotype, as has been recently demonstrated in breast cancer \[[@B23-cancers-09-00030]\]. This suggests that the context (both temporal and cellular) in which the mutation occurs determines its phenotype, conferring heterogeneity to the spectrum of disease burden.

On the other hand, germline loss-of-function mutations of PTEN and TSC1/TSC2 cause PTEN hamartoma tumor syndrome and tuberous sclerosis complex. In all these conditions, the affected sites show increased activation of the PI3K and mTOR pathways, together with an increased proliferation rate of the tissue involved.

PI3K/mTOR-dependent aberrant growth can also affect several tissues, including kidneys, where it results in cyst formation.

3. The PIK3CA-Related Spectrum of Overgrowth Syndromes {#sec3-cancers-09-00030}
======================================================

It has been reported that PI3K pathway components are somatically mutated in a spectrum of congenital or early-childhood-onset human disorders \[[@B24-cancers-09-00030],[@B25-cancers-09-00030]\]. Some of these de novo mutations are usually somatic, as the corresponding germline mutations would lead to extremely pervasive developmental disorders, which would result in embryonic lethality \[[@B26-cancers-09-00030]\]. A common feature of these disorders is the aberrant activation of cellular proliferation pathways and overgrowth, which have been therefore referred-to as "overgrowth syndromes". Although each syndrome has a specific panel of clinical features, some overlapping characteristics can be determined. Similarly, such a phenotypic overlap was previously recognized for the large group of RAS-related syndromes, collectively referred-to as "RASopathies", which are caused by activating mutations affecting RAS signaling components \[[@B27-cancers-09-00030]\], and mainly occurring in the germline (albeit mosaic RASopathies have also been identified) \[[@B28-cancers-09-00030]\].

The overgrowth syndromes comprise a wide group of clinically recognizable mutation-driven congenital malformations \[[@B29-cancers-09-00030]\]. Among these, the PIK3CA-related overgrowth spectrum (PROS) congenital disorders are caused by a range of mosaic-activating mutations in the PIK3CA gene, coding for p110α.

The different mutations underlying PROS disorders result in moderate-to-strong constitutive activation of PIK3CA ([Table 1](#cancers-09-00030-t001){ref-type="table"}), leading to the increased growth of the affected tissues \[[@B30-cancers-09-00030]\]. The PROS spectrum is broad, from weak phenotypes to dramatic malformations, reflecting the effect of mutations during embryogenesis and in progenitor cells \[[@B31-cancers-09-00030]\]. Within PROS, some distinct entities can be recognized, despite considerable overlap.

Cutaneous defects together with developmental neurological abnormalities are normally present in macrocephaly-capillary malformation (MCAP) and CLOVES. In addition, several disorders are associated with connective tissue overgrowth, presumably arising from mutations affecting progenitor cells committed to a mesenchymal fate. Of note, MCAP can be occasionally caused by germline PIK3CA mutations \[[@B32-cancers-09-00030]\]. Malignancies are rare in the PROS spectrum \[[@B24-cancers-09-00030]\], even if PIK3CA is the most common mutated gene in cancer.

Another class of overgrowth diseases, the PTEN hamartoma tumor syndrome (PHTS), is caused by mutations in the PTEN tumor suppressor gene. In particular, heterozygous inactivating germline genetic lesions occur in the PTEN gene and they are responsible for 90% of Cowden syndrome (CS) cases. CS has a wide clinical spectrum, including skin abnormalities, macrocephaly and predisposition to multiple cancer types, including breast, colon and thyroid \[[@B33-cancers-09-00030]\]. In segmental overgrowth, lipomatosis, arteriovenous malformation, and epidermal nevus (SOLAMEN), classic manifestations of CS are combined with segmental overgrowth, arteriovenous and lymphatic malformations, lipomas, and epidermal nevi. SOLAMEN symptoms are related to mosaic loss of the healthy PTEN allele in patients carrying a germline PTEN mutation \[[@B34-cancers-09-00030]\]. This phenomenon, known as type 2 mosaicism, has been extensively documented for other genetic disorders. Interestingly, the patients do not develop malignancies in the tissues affected by PTEN loss.

In 2011, Lindhurst et al. reported a mosaic-activating AKT1 mutation that causes Proteus syndrome (PS) \[[@B35-cancers-09-00030]\], which is associated with prominent skin and vascular malformations. In addition, the other AKT family members, AKT2 and AKT3, have also been implicated in overgrowth syndromes \[[@B32-cancers-09-00030],[@B36-cancers-09-00030]\].

While most of the previous studies have been focused on germline mutations, thanks to deep-sequencing technologies, there is increased evidence that somatic mutations also are related to non-cancer phenotypes. However, there are no available mouse models that fully recapitulate the wide spectrum of phenotypes which characterize PI3KCA-related overgrowth syndromes.

4. PI3Ks Inhibitors as a Therapeutic Challenge in Overgrowth Syndromes {#sec4-cancers-09-00030}
======================================================================

Due to the extensiveness of vascular malformations and tissue overgrowth, PI3K-related syndromes pose a therapeutic challenge. Sclerotherapy or surgery might improve symptoms or ameliorate patients' appearance, but complete remission is seldom seen. As genetic alterations in PI3K/AKT/mTOR signaling have been recognized as pivotal cancer drivers, considerable efforts have been employed to generate a plethora of inhibitors for such pathway components. Several of these compounds are in clinical trials for cancer and may be reasonably re-purposed as targeted therapies for overgrowth conditions \[[@B44-cancers-09-00030]\]. Recently, an association between somatic mutations in PIK3CA and sporadic venous malformations in mouse models have been demonstrated \[[@B45-cancers-09-00030],[@B46-cancers-09-00030]\]. Both studies highlighted the efficacy of selective PI3Kα and mTOR inhibitors to reduce the size and proliferation of these malformations. Even if there are not any clinical trials to evaluate PI3K p110α inhibitors in PROS, pre-clinical studies in both PROS and cancers bearing PIK3CA mutations have yielded promising results \[[@B30-cancers-09-00030]\].

Several AKT inhibitors are now in clinical trials for cancer. Notably, a phase I trial of ARQ 092, a pan-AKT inhibitor, is underway in children and adults with Proteus syndrome (ClinicalTrials.gov: NCT02594215). Allosteric inhibitors of mTOR, including sirolimus (rapamycin), everolimus, ridaforolimus, temsirolimus, are licensed therapies for a range of conditions \[[@B47-cancers-09-00030]\]. Notably, off-label applications of mTOR inhibitors might be successfully exploited also in non-cancer diseases. Very recently, rapamycin has been suggested as a systemic therapy to reduce vascular malformations in patients \[[@B48-cancers-09-00030],[@B49-cancers-09-00030]\], including those carrying PTEN mutations \[[@B50-cancers-09-00030],[@B51-cancers-09-00030]\]. A clinical trial investigating sirolimus in PROS (ClincalTrials.gov: NCT02428296) is currently underway, with expected completion in 2017. Of greatest relevance to PI3K/AKT-related disorders are dual PI3K-mTOR inhibitors, which are currently in phase I trial for cancer \[[@B52-cancers-09-00030]\].

Of note, patients with somatic activation of the PI3K/AKT pathway may need life-long therapy with the inhibitor. This raises concern not only for the more common adverse effects of these inhibitors, but also for unknown effects that cannot be revealed by short-term evaluation in clinical trials, this being a critical challenge which already emerged for RAS-related syndromes. Unfortunately, data from preclinical studies in a disease model are scarce. Recently, Kinross et al. systemically overexpressed the H1047R mutation of PIK3CA, leading to increased body weight with enlarged organs due to increased cell number \[[@B53-cancers-09-00030]\]. In addition, Hare et al. overexpressed the PIK3CA H1047R mutation specifically in endothelial cells, leading to extensive vascular remodeling and embryonic lethality \[[@B54-cancers-09-00030]\].

5. PI3Ks as a Master Controller of Proliferation in the Kidney and in Polycystic Kidney Disease {#sec5-cancers-09-00030}
===============================================================================================

Besides cancer \[[@B1-cancers-09-00030]\] and overgrowth syndromes \[[@B44-cancers-09-00030]\], alterations in the PI3K/AKT/mTOR pathway are major drivers of abnormal proliferation. In the kidney, the hyper-proliferation of tubular cells induces renal cyst formation, which can be considered a sort of overgrowth syndrome and is typical of polycystic kidney disease (PKD). In this context, the increased proliferation can be caused by opposite genetic lesions occurring in PI3Ks: on one side, hyper-activation of the AKT-dependent class I PI3KCA signaling pathway, on the other side, loss of class II PI3K-C2α.

In PKD, it is well described that alterations of several components of the PI3K/AKT/mTOR pathway, already found in cancer, are implicated in the hyper-proliferation of renal tubular cells, such as TSC. TSC is a well-known tumor suppressor, which is negatively regulated by AKT and acts as a GTPase Activating Protein (GAP) for the small GTPase Rheb, thus leading to mTORC1 inhibition. TSC1 and TSC2 genes are mutated in a genetic disorder called tuberous sclerosis complex (TSC). TSC causes the development of hamartomas, which can arise in multiple organs, including brain, kidney, skin and liver. Humans and mice with loss of either TSC1 or TSC2 are prone to developing renal problems including cysts, which usually do not interfere with kidney function \[[@B55-cancers-09-00030]\]. However, in a small subset of patients with loss of TSC and who were affected by severe infantile polycystic kidney disease, cysts led to renal failure \[[@B56-cancers-09-00030]\]. It was reported that conditional knockout of TSC1 in renal tubular cells resulted in PKD \[[@B57-cancers-09-00030]\]. Both the hyper-activation of class I PI3KCA and the inhibition of TSC result in the mTOR-mediated increase in cell proliferation. Besides its AKT-mediated inhibition, TSC can be activated by polycystins. Polycistin-1 acts as a mechanosensor of the fluid flux and activates the calcium channel Polycistin-2. These two transmembrane proteins are encoded by PKD1 or PKD2 genes, which are mutated in autosomal-dominant polycystic kidney disease (ADPKD), a genetic disorder characterized by uncontrolled proliferation of renal cells with the consequent formation of cysts and loss of renal function \[[@B58-cancers-09-00030],[@B59-cancers-09-00030]\]. The anti-proliferative signal of polycystins due to mTORC1 inhibition is mediated by TSC1 and TSC2 genes. Mice with concomitant loss of TSC and PC1 revealed that cyst development is closely correlated with elevated mTORC1 activity, leading to hypertrophy and increased proliferation of the renal tubular cells \[[@B60-cancers-09-00030]\]. In cells, the coexistence of mutation and loss of TSC alleles presented an alteration in the localization of PC1 on the plasma membrane \[[@B57-cancers-09-00030]\]. Re-expression of PC1 in the TSC1-mutant kidneys corrects the phenotype. On the other hand, mTORC1 acts in a negative feedback loop to downregulate PC1 expression levels. Consistently, the inhibition of mTOR increases the expression levels of polycystins and slows cyst expansion \[[@B60-cancers-09-00030],[@B61-cancers-09-00030]\].

Conversely, mTOR activation is also triggered by the loss of a class II PI3K-C2α, which is important for the correct transport of Polycystins along the primary cilium. Polycystins exert their function only when properly localized on this organelle \[[@B62-cancers-09-00030]\]. The localization of PC2, in turn, is required for a correct transduction of the anti-proliferative signal, inhibiting intracellular pathways, including the mTOR and mitogen-activated protein kinase (MAPK) pathways, eventually avoiding cystogenesis \[[@B63-cancers-09-00030]\]. The transport of PC2 along the primary cilium is mediated by the small guanosine triphosphatase (GTPase) RAB8, which in turn is regulated by RAB11. It was demonstrated that PI3K-C2α acts at the pericentriolar recycling endosomal compartment (PRE) at the base of the primary cilium where it produces PI(3)P and promotes RAB11 activation upstream of RAB8 \[[@B6-cancers-09-00030],[@B7-cancers-09-00030],[@B64-cancers-09-00030]\]. The inhibition of PI3K-C2α decreases the number of PC2-positive cilia, resulting in increased mTOR and MAPK signaling. Accordingly, the expression of a constitutive active form of RAB8 (RAB8^Q67L^) is able to restore these defects. Indeed, the concomitant heterozygous loss of PI3K-C2α and PC1 or PC2 correlates with a higher number of cysts in proximal and distant tubules. These data indicate that PI3K-C2α activates the RAB11/RAB8 cascade, regulating the transport of cargo proteins, such as polycystins, along the primary cilium, thus preventing cyst formation \[[@B7-cancers-09-00030]\]. These data point out that uncontrolled proliferation is due to the hyper-activation of class I PI3KCA or loss of class II PI3K-C2α. For class I PI3K, the proliferation signal is induced by the PI(3,4,5)P3-mediated activation of AKT, which in turn enhances mTOR activity. On the contrary, for class II PI3K, cell proliferation seems to be triggered by polycystin-mediated inhibition of mTOR. The apparent contradiction of these different PI3Ks could be explained by the lack of the AKT-activating PI(3,4,5)P3 production by class II PI3K. Consistently, PI3K-C2β knockout enhances insulin/AKT signaling in metabolic tissues, probably due to a compensatory enhancement of class I PI3K activation, which produces PI(3,4,5)P3 and activates AKT \[[@B65-cancers-09-00030]\].

In the prevention of cyst formation, negative regulators of PI3Ks, including PTEN, are implicated. PTEN loss per se is not sufficient to induce cyst development \[[@B66-cancers-09-00030]\]; conversely, the concomitant loss of PTEN and other tumor suppressor genes, such as Von Hippel-Lindau (VHL) and TSC, was implicated in cyst formation. VHL syndrome is a familiar cancer which predisposes to a variety of malignant and benign tumors. In some patients, kidney cysts are precursor lesions for clear cell renal cell carcinoma (ccRCC), one the most common malignant kidney tumors. Cysts in human VHL patients, but not VHL mutant cells, display hyper-activation of the PI3K/AKT/mTOR signaling pathways, indicating that PI3K mutations may be an early event in the transformation process. Double-knockout mice for PTEN and VHL showed enlarged and heavier kidneys due to multiple cysts, characterized by a lack of primary cilium, increased proliferation and activated PI3K signaling \[[@B67-cancers-09-00030],[@B68-cancers-09-00030]\]. Similarly, it was reported that mice lacking PTEN and TSC1 develop severe PKD \[[@B66-cancers-09-00030]\]. This suggests that concomitant mutations are needed to induce cyst development in a cancer-prone background.

A recent study identified a four-gene signature as a prognostic value for ccRCC, including PTEN, PIK3C2A, ITPA and BCL3 \[[@B69-cancers-09-00030]\]. Moreover, low expression of PTEN and PIK3C2A was correlated with high risk and poor prognosis \[[@B69-cancers-09-00030]\].

By now, the only available therapies for ADPKD are supportive treatments, such as regulation of blood pressure, and dialysis or kidney transplantation are often required. Given the concomitant alterations of pathways other than mTOR, the efficiency of molecular target therapies, such as sorafenib and temsirolimus, is limited to 10%--40%. Preclinical trials based on mTOR inhibition (mTOR-I) by either the immunosuppressant sirolimus (SIR) \[[@B61-cancers-09-00030],[@B70-cancers-09-00030]\] or everolimus (EVER) \[[@B71-cancers-09-00030]\] demonstrated that the sirolimus injection led to increased kidney size, cyst density and tubular cell proliferation. However, in clinical trials only negligible effects on cyst growth and preservation of renal function were observed, due to the development of resistance \[[@B72-cancers-09-00030],[@B73-cancers-09-00030]\]. In particular, it was demonstrated that sirolimus treatment may restore a cell's ability to activate AKT, suggesting that patients with TSC show a high risk of malignant tumor development due to long-term treatment \[[@B74-cancers-09-00030]\]. Up to now, the most important supportive treatment for ADPKD is the regulation of blood pressure. A clinical trial for tolvaptan, a vasopressin 2 receptor (V2R) antagonist, is still under Food and Drug Administration (FDA) approval, due to the request for further information about side effects and selection of patient cohorts who may benefit from treatment (clinicaltrials.gov). As V2R is a GPCR-coupled receptor whose downstream pathway is mediated by PI3Ks, we can speculate that the targeting of PI3K itself, but not mTOR, could be beneficial in the treatment of ADPKD.

6. Conclusions {#sec6-cancers-09-00030}
==============

PI3K/AKT/mTOR is frequently deregulated in several proliferative disorders, from cancer to overgrowth syndromes and polycystic kidney disease. Despite similar mutations, patients develop a plethora of different disorders. For example, PIK3CA mutations associated with overgrowth syndromes are often similar to those observed in cancer, but these patients do not seem to be predisposed to cancer. Similarly, loss of tumor suppressor genes such as TSC1 and TSC2 is not always accompanied by the development of renal cysts and overgrowth. This suggests that the role of mutations in disease is determined by the context in which they occur. Clinical variability may depend on the timing of the mutation during embryogenesis, the type of tissue affected and concomitant secondary lesions. On the other hand, the common molecular basis of these disorders is associated with significant clinical overlap. This will eventually help to apply the therapeutic strategies used for well-studied pathologies, such as cancer, to emerging clinically relevant diseases, such as overgrowth syndrome and polycystic kidney disease. Conversely, patients with ADPKD did not benefit from rapalogs treatment, indicating that mTOR-mediated signaling is not the only pathway involved in cyst formation. These clinical failures imply that a novel therapeutic option could be based on the single or combined targeting of PI3K pathway components.

This work was supported by Associazione Italiana Ricerca Cancro (AIRC) (161813), Compagnia di San Paolo and the World Wide Cancer Research Association (formerly known as AICR) (151324). M.M. is supported by a Fondazione Umberto Veronesi fellowship.

The authors declare no conflict of interest.

cancers-09-00030-t001_Table 1

###### 

PIK3CA-related overgrowth spectrum (PROS). PIK3CA predicted mutations and associated clinical overgrowth disorders (for a comprehensive study please see Keppler-Noreuil 2015) \[[@B31-cancers-09-00030]\]).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical PROS Disorder                                                                                                                              Mutation (Gene Domain)                             References
  --------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------- -----------------------------------------------------------------------------
  Megalencephaly-capillary malformation syndrome (MCAP)                                                                                               E81K, R88Q (p85 BD)\                               \[[@B32-cancers-09-00030]\]
                                                                                                                                                      G364R, E365K, C378Y, E452K, E453K, E453del (C2)\   
                                                                                                                                                      E542K, E545K (Helical)\                            
                                                                                                                                                      E726K\                                             
                                                                                                                                                      G914R, Y1021C, T1025A, A1035V (Kinase)\            
                                                                                                                                                      H1047L, H1047R, M1043I, H1047Y, G1049S (Kinase)    

  Congenital lipomatous overgrowth, vascular malformations, linear keratinocytic epidermal nevi, and skeletal or spinal anomalies (CLOVES) syndrome   C420R\                                             \[[@B24-cancers-09-00030],[@B37-cancers-09-00030],[@B38-cancers-09-00030]\]
                                                                                                                                                      E542K, E545K (Helical)\                            
                                                                                                                                                      H1047L, H1047R (Kinase)                            

  Fibroadipose overgrowth (FAO)/Hemihyperplasia multiple lipomatosis (HHML)                                                                           E542K, E545K (Helical)\                            \[[@B39-cancers-09-00030],[@B40-cancers-09-00030]\]
                                                                                                                                                      H1047L, H1047R (Kinase)                            

  Macrodactyly                                                                                                                                        R115P\                                             \[[@B41-cancers-09-00030]\]
                                                                                                                                                      E542K, E545K (Helical)\                            
                                                                                                                                                      H1047L, H1047R (Kinase)                            

  Hemimegalencephaly                                                                                                                                  E542K, E545K (Helical)                             \[[@B42-cancers-09-00030]\]

  Muscle hemihyperplasia                                                                                                                              E542K, E545K (Helical)\                            \[[@B41-cancers-09-00030]\]
                                                                                                                                                      H1047L, H1047R, L1067fs (Kinase)                   

  Facial infiltrating lipomatosis                                                                                                                     E452K, E453K, E453del (C2)\                        \[[@B43-cancers-09-00030]\]
                                                                                                                                                      E542K, E545K (Helical)\                            
                                                                                                                                                      H1047L, H1047R (Kinase)                            

  Epidermal nevi                                                                                                                                      E542K, E545K (Helical)\                            \[[@B19-cancers-09-00030]\]
                                                                                                                                                      H1047L, H1047R (Kinase)                            

  Seborrheic keratoses                                                                                                                                E542K, E545K (Helical)\                            \[[@B19-cancers-09-00030]\]
                                                                                                                                                      H1047L, H1047R (Kinase)                            

  Benign lichenoid keratoses                                                                                                                          E542K, E545K (Helical)                             \[[@B19-cancers-09-00030]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: These authors equally contributed to this work.